These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 2185723)

  • 1. A randomized placebo-controlled trial of cysteamine eye drops in nephropathic cystinosis.
    Kaiser-Kupfer MI; Gazzo MA; Datiles MB; Caruso RC; Kuehl EM; Gahl WA
    Arch Ophthalmol; 1990 May; 108(5):689-93. PubMed ID: 2185723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of topical cysteamine in nephropathic cystinosis.
    Al-Hemidan A; Shoughy SS; Kozak I; Tabbara KF
    Br J Ophthalmol; 2017 Sep; 101(9):1234-1237. PubMed ID: 28057644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Removal of corneal crystals by topical cysteamine in nephropathic cystinosis.
    Kaiser-Kupfer MI; Fujikawa L; Kuwabara T; Jain S; Gahl WA
    N Engl J Med; 1987 Mar; 316(13):775-9. PubMed ID: 3821824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of topical cysteamine drops on reducing crystal formation within the cornea of patients affected by nephropathic cystinosis.
    MacDonald IM; Noel LP; Mintsioulis G; Clarke WN
    J Pediatr Ophthalmol Strabismus; 1990; 27(5):272-4. PubMed ID: 2246744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized clinical trial of topical cysteamine disulfide (cystamine) versus free thiol (cysteamine) in the treatment of corneal cystine crystals in cystinosis.
    Iwata F; Kuehl EM; Reed GF; McCain LM; Gahl WA; Kaiser-Kupfer MI
    Mol Genet Metab; 1998 Aug; 64(4):237-42. PubMed ID: 9758713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clearance of corneal crystals in nephropathic cystinosis by topical cysteamine 0.5%.
    Jones NP; Postlethwaite RJ; Noble JL
    Br J Ophthalmol; 1991 May; 75(5):311-2. PubMed ID: 2036352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised placebo-controlled trial of topical cysteamine therapy in patients with nephropathic cystinosis.
    Bradbury JA; Danjoux JP; Voller J; Spencer M; Brocklebank T
    Eye (Lond); 1991; 5 ( Pt 6)():755-60. PubMed ID: 1800180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cysteamine eyedrops for treatment of corneal cysteine deposits in infantile cystinosis].
    Gräf M; Grote A; Wagner F
    Klin Monbl Augenheilkd; 1992 Jul; 201(1):48-50. PubMed ID: 1513127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NIH conference. Cystinosis: progress in a prototypic disease.
    Gahl WA; Thoene JG; Schneider JA; O'Regan S; Kaiser-Kupfer MI; Kuwabara T
    Ann Intern Med; 1988 Oct; 109(7):557-69. PubMed ID: 3048161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful use of topical cysteamine formulated from the oral preparation in a child with keratopathy secondary to cystinosis.
    Khan AO; Latimer B
    Am J Ophthalmol; 2004 Oct; 138(4):674-5. PubMed ID: 15488810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new gel formulation of topical cysteamine for the treatment of corneal cystine crystals in cystinosis: the Cystadrops OCT-1 study.
    Labbé A; Baudouin C; Deschênes G; Loirat C; Charbit M; Guest G; Niaudet P
    Mol Genet Metab; 2014 Mar; 111(3):314-320. PubMed ID: 24440466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops.
    Gahl WA; Kuehl EM; Iwata F; Lindblad A; Kaiser-Kupfer MI
    Mol Genet Metab; 2000; 71(1-2):100-20. PubMed ID: 11001803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nephropathic cystinosis in children: An overlooked disease.
    Soliman NA; El-Baroudy R; Rizk A; Bazaraa H; Younan A
    Saudi J Kidney Dis Transpl; 2009 May; 20(3):436-42. PubMed ID: 19414947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A New Viscous Cysteamine Eye Drops Treatment for Ophthalmic Cystinosis: An Open-Label Randomized Comparative Phase III Pivotal Study.
    Liang H; Labbé A; Le Mouhaër J; Plisson C; Baudouin C
    Invest Ophthalmol Vis Sci; 2017 Apr; 58(4):2275-2283. PubMed ID: 28426870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cysteamin eyedrops in three patients with nephropathic cystinosis.
    Blanksma LJ; Jansonius NM; Reitsma-Bierens WC
    Doc Ophthalmol; 1996-1997; 92(1):51-3. PubMed ID: 9181332
    [No Abstract]   [Full Text] [Related]  

  • 16. Evolution of ocular manifestations in nephropathic cystinosis: a long-term study of a population treated with cysteamine.
    Dureau P; Broyer M; Dufier JL
    J Pediatr Ophthalmol Strabismus; 2003; 40(3):142-6. PubMed ID: 12795432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ocular treatment of cystinosis with eye drop containing cysteamine].
    Csorba A; Maka E; Szabó A; Kelen K; Reusz G; Nagy ZZ
    Orv Hetil; 2022 May; 163(21):846-852. PubMed ID: 35598215
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Ozdemir HB; Özmen MC; Aktas Z; Hasanreisoglu M
    Indian J Ophthalmol; 2019 Jan; 67(1):153-155. PubMed ID: 30574930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gel formulations for treatment of the ophthalmic complications in cystinosis.
    Buchan B; Kay G; Heneghan A; Matthews KH; Cairns D
    Int J Pharm; 2010 Jun; 392(1-2):192-7. PubMed ID: 20382212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic Cysteamine Delivery Nanowafer as an Efficacious Treatment Modality for Corneal Cystinosis.
    Marcano DC; Shin CS; Lee B; Isenhart LC; Liu X; Li F; Jester JV; Pflugfelder SC; Simpson J; Acharya G
    Mol Pharm; 2016 Oct; 13(10):3468-3477. PubMed ID: 27571217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.